Cardiovascular effects of the addition of nilotinib to standard therapy for acute myeloid leukemia

Carolyn M. LarsenDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA;

http://orcid.org/0000-0001-6530-3545 View further author information

Hector R. VillarragaDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA; View further author information

Kebede H. BegnaDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USAView further author information

Mark R. LitzowDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA

http://orcid.org/0000-0002-9816-6302 View further author information

Aref Al-KaliDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA

http://orcid.org/0000-0002-0824-3715 View further author information

Joerg HerrmannDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA; Correspondence[email protected]
View further author information

Click to increase image sizeClick to decrease image size

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2017.1323268.

Additional information

Funding

Novartis Pharmaceuticals Corp. supported the research of Dr. Al Kali. Novartis Pharmaceuticals Corporation provided financial support for this work through their support of the DATA trial.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Cardiovascular effects of the addition of nilotinib to standard therapy for acute myeloid leukemia

Information for

Open access

Opportunities

Help and information

Cardiovascular effects of the addition of nilotinib to standard therapy for acute myeloid leukemia

Potential conflict of interest

Additional information

Funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature